Hancept’s wildly innovative Zero Mk2 EDC pen is here to smash that excuse once and for all. It might just be the most ...
Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...